Q-Line Biotech Limited

specific focus on Utter Pradesh, Rajasthan, Madhya Pradesh, Kerala and Odisha. We focus on products which are identified based on research, analysis of market trends and demand trends in the regions, we cater. Our sales to the above-mentioned focus area contributed 87%, 81%, and 83%, of our total revenue from operations for the Financial Year 2025, 2024 & 2023 on standalone basis respectively.

(In lakhs)

<table><thead><tr><th>Particulars</th><th>FY23</th><th>%</th><th>FY24</th><th>%</th><th>24-25</th><th>%</th></tr></thead><tbody><tr><td><strong>Consumable/Spare</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Consumable/Spare and Accessories</td><td>1,040.49</td><td>5.69%</td><td>607.83</td><td>2.98%</td><td>1,415.13</td><td>4.51%</td></tr><tr><td><strong>Instrument</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical Chemistry Analyzer</td><td>2,016.43</td><td>11.03%</td><td>2,692.70</td><td>13.22%</td><td>7,616.46</td><td>24.28%</td></tr><tr><td>Haematology Analyzer</td><td>1,193.83</td><td>6.53%</td><td>2,411.86</td><td>11.84%</td><td>3,292.84</td><td>10.50%</td></tr><tr><td>Others</td><td>699.09</td><td>3.83%</td><td>565.12</td><td>2.78%</td><td>584.7</td><td>1.86%</td></tr><tr><td><strong>Reagent</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical Chemistry Reagents</td><td>7,175.00</td><td>39.26%</td><td>7,936.94</td><td>38.97%</td><td>11,314.38</td><td>36.07%</td></tr><tr><td>Haematology Reagent</td><td>4,175.24</td><td>22.85%</td><td>4,095.27</td><td>20.11%</td><td>5,086.48</td><td>16.21%</td></tr><tr><td>Others</td><td>1,796.56</td><td>9.83%</td><td>1,547.42</td><td>7.60%</td><td>1,238.76</td><td>3.95%</td></tr><tr><td><strong>Service</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Annual Maintenance Contracts</td><td>177</td><td>0.97%</td><td>507.47</td><td>2.49%</td><td>822.36</td><td>2.62%</td></tr><tr><td><strong>Total</strong></td><td><strong>18,273.63</strong></td><td><strong>100.00%</strong></td><td><strong>20,364.61</strong></td><td><strong>100.00%</strong></td><td><strong>31,371.09</strong></td><td><strong>100.00%</strong></td></tr></tbody></table>

Our product portfolio comprises a mix of reagents, point of care devices, kits, diagnostic instruments, equipment, consumables and services used in different testing like clinical chemistry, coagulation, haematology, HPLC, rapid/elisa, molecular etc. Further, sales of our reagents and diagnostic instruments contributed 17639.61 lakhs and 11494.00 lakhs of our revenue from operation for the period March 31, 2025 and contributed 13579.63 Lakhs and 5669.69 lakhs of our revenue from operation for the financial year March 2024, respectively. Our diverse product portfolio and geographic presence provide us with a risk-mitigated business model, enabling us to derive resilience from multiple revenue streams while leveraging our manufacturing and R&D capabilities.

### Widespread distribution network with a presence across all four regions

We maintain a comprehensive marketing and distribution infrastructure to support sales and service for our customers, complemented by our distributor network for efficient logistics and supply chain management. As of March 31, 2025, our field operations comprise 93 sales personnel and 37 service engineers, ensuring market coverage and customer support. Our sales representatives regularly visit laboratories, hospitals, institutions, clinical research organizations, and distributor facilities to promote our product portfolio and ensure adequate stock availability of our brands. We prioritize building relationships with our customers and distributors, for our business growth and market penetration. Our presence enables us to provide timely technical support, conduct product demonstrations, deliver application training, and maintain strong customer engagement across our target markets. Our integrated approach to sales and service ensures customer satisfaction and supports the expansion of our market reach. We cater mainly the Northen region and sell some portion of our sales to other regions across the India and plan to expand in international market.

### Long standing relationships with customers.

Our customer engagements are dependent on us delivering quality products, consistently. During the Fiscal 2025, 2024 and Fiscal 2023, we served 963, 1005 and 828 customers, respectively. We have served 1642 customers in the last three (3) financial years and during the financial year ended March 31, 2025 there are 361 customers of total customers who placed repeated orders in all the last 3 years. Out of our total revenue from operations in the Fiscals 2025, 2024 and 2023, our top 10 customers amounted ₹ 25778.68 lakhs, ₹ 15737.91, ₹ 13991.30 and ₹ contributing 82.17%, 77.28%, and 76.57% respectively. Our long-term relationships and ongoing engagements with customers, allow us to plan our working capital and capital expenditure, enhance our ability to benefit from economies of scale with stronger purchasing power for raw materials and a lower cost base. These customer relationships have also helped us in expanding our product offerings and geographic reach. Our customer base assists us in reducing dependence and helps in mitigating the effects of economic and industry-specific cycles.

### Track record of healthy financial performance

We have established a track of consistent revenue growth and profitability. Our revenue from operations increased from ₹18273.63 lakhs in Fiscal 2023 to ₹31378.04 lakhs in Fiscal 2025 at a CAGR of 31.04%. Further, our total income increased from ₹ 18481.15 lakhs in Fiscal 2023 to ₹ 32258.42 lakhs in Fiscal 2025 and our total assets increased from ₹ 25157.96 lakhs as of March 31, 2023 to ₹ 45548.59 lakhs as of March 31, 2025. We believe that our continued focus on efficiency, productivity improvements and cost rationalization have enabled us keep our operating costs under control and improve our margins. Our adjusted EBITDA has increased from ₹ 3297.72 lakhs in Fiscal 2023 to ₹ 7132.12 lakhs in Fiscal 2025 while our EBITDA Margin increased from 18.05% in Fiscal 2023 to 22.73% in Fiscal 2025. In Fiscal 2025, 2024 and 2023, our Return on Capital Employed was 17.66%, 19.25%, and 22.14%, respectively and as of March 31, 2025, 2024 and 2023, our Return on Equity was 15.99%, 23.83% and 29.49%, respectively. We believe that we have utilized our resources prudently, and that our operational and financial performance will allow us to take